Get the latest tech news
AI Drug Startup Insilico Weighs Hong Kong IPO After Funding
Insilico Medicine Inc. is considering an initial public offering after securing funding at a valuation of more than $1 billion, reflecting growing interest in the potential use of AI to discover ground-breaking new drugs.
A lab inside Insilico Medicine's research facility in Suzhou, China. Photographer: Qilai Shen/Bloomberg
Or read this on Bloomberg